Daniel Lasanow
Chairman bei Polypeptide Laboratories France SAS
Vermögen: 261 286 $ am 31.03.2024
Profil
Daniel Lasanow currently works at Polypeptide Laboratories France SAS, as Chairman from 2017.
Mr. Lasanow also formerly worked at Lonza, Inc., as Production Director, NextPharma Technologies SA (Belgium), as Production Director from 2009 to 2011, UCB-Bioproducts SA, as Production Director, and PolyPeptide Group AG, as Director-Global Operations from 2016 to 2022.
Mr. Lasanow received his graduate degree from Université Catholique de Louvain.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
POLYPEPTIDE GROUP AG
0,02% | 31.12.2022 | 7 767 ( 0,02% ) | 261 286 $ | 31.03.2024 |
Aktive Positionen von Daniel Lasanow
| Unternehmen | Position | Beginn |
|---|---|---|
Polypeptide Laboratories France SAS
 Polypeptide Laboratories France SAS Chemicals: SpecialtyProcess Industries Part of PolyPeptide Group AG, Polypeptide Laboratories France SAS is a contract manufacturer of organic peptides. The private company is based in Strasbourg, France. | Chairman | 10.04.2017 |
Ehemalige bekannte Positionen von Daniel Lasanow
| Unternehmen | Position | Ende |
|---|---|---|
| POLYPEPTIDE GROUP AG | Chief Operating Officer | 30.11.2022 |
| NextPharma Technologies SA (Belgium) | Corporate Officer/Principal | 01.01.2011 |
UCB-Bioproducts SA
 UCB-Bioproducts SA Miscellaneous Commercial ServicesCommercial Services UCB-Bioproducts is a Belgian based, international Contract Services Company, focusing on custom peptide and peptidomimetics (for pharmaceutical use) process development, regulatory services and manufacturing services along with strong support to customers' clinical trials. UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the lives of people. | Corporate Officer/Principal | - |
Lonza, Inc.
 Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Corporate Officer/Principal | - |
Ausbildung von Daniel Lasanow
| Université Catholique de Louvain | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| POLYPEPTIDE GROUP AG | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Lonza, Inc.
Lonza, Inc. Chemicals: SpecialtyProcess Industries Lonza, Inc. provides chemical ingredient products. The company is headquartered in Allendale, NJ. | Process Industries |
| NextPharma Technologies SA (Belgium) | |
UCB-Bioproducts SA
UCB-Bioproducts SA Miscellaneous Commercial ServicesCommercial Services UCB-Bioproducts is a Belgian based, international Contract Services Company, focusing on custom peptide and peptidomimetics (for pharmaceutical use) process development, regulatory services and manufacturing services along with strong support to customers' clinical trials. UCB-Bioproducts mission is to create value by supporting pharmaceutical players to bring innovative drugs to the market to improve the lives of people. | Commercial Services |
Polypeptide Laboratories France SAS
Polypeptide Laboratories France SAS Chemicals: SpecialtyProcess Industries Part of PolyPeptide Group AG, Polypeptide Laboratories France SAS is a contract manufacturer of organic peptides. The private company is based in Strasbourg, France. | Process Industries |
